Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total Revenues	$ 33	$ 28
Costs and Expenses:
Production costs	77	237
Research and development	1,036	1,424
General and administrative	2,072	2,112
Total Costs and Expenses	3,185	3,773
Operating loss	(3,152)	(3,745)
(Loss) on investments	(934)
Interest and other income	45	72
Interest expense and other finance costs		(50)
Redeemable warrants valuation adjustment	31	(37)
Gain from sale of income tax operating losses	190	181
Net Loss	(3,820)	(3,579)
Other comprehensive loss
Reclassification adjustment for realized investment loss		2
Change in unrealized loss on marketable securities available for sale		(163)
Net comprehensive loss	$ (3,820)	$ (3,740)
Basic and diluted loss per share	$ (0.08)	$ (0.08)
Weighted average shares outstanding basic and diluted	47,994,672	45,726,855
Clinical Treatment Programs US [Member]
Revenues:
Total Revenues	$ 33	$ 28
Clinical Treatment Programs Europe [Member]
Revenues:
Total Revenues